Tiago Fauth
Stock Analyst at Wells Fargo
(0.90)
# 2,788
Out of 4,413 analysts
99
Total ratings
25%
Success rate
-22.11%
Average return
Main Sectors:
Top Industries:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTE Aerovate Therapeutics | Maintains: Overweight | $35 | $20.01 | +74.91% | 1 | Apr 1, 2024 | |
| INSM Insmed | Maintains: Overweight | $55 | $24.72 | +122.49% | 1 | Apr 1, 2024 | |
| UTHR United Therapeutics | Maintains: Overweight | $309 → $325 | $234.33 | +38.69% | 2 | Mar 7, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $171 → $161 | $143.95 | +11.84% | 2 | Feb 16, 2024 | |
| KROS Keros Therapeutics | Initiates: Overweight | $60 | $56.39 | +6.40% | 1 | Dec 8, 2023 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Overweight | $72 | $42.54 | +69.25% | 5 | Dec 8, 2023 | |
| VTYX Ventyx Biosciences | Maintains: Outperform | $63 → $62 | $3.74 | +1,557.75% | 5 | Aug 11, 2023 | |
| ASND Ascendis Pharma | Assumes: Neutral | $89 | $138.44 | -35.71% | 14 | Jun 14, 2023 | |
| VRDN Viridian Therapeutics | Assumes: Outperform | $51 | $13.26 | +284.62% | 3 | Jun 14, 2023 | |
| BMRN BioMarin Pharmaceutical | Assumes: Outperform | $120 | $80.76 | +48.59% | 7 | Jun 14, 2023 | |
| ME 23andMe Holding Co. | Reiterates: Outperform | $6 | $0.50 | +1,094.74% | 6 | May 26, 2023 | |
| IMVT Immunovant | Reiterates: Underperform | $4 | $27.44 | -85.42% | 4 | May 23, 2023 | |
| ABSI Absci | Reiterates: Outperform | $14 | $4.74 | +195.36% | 4 | May 16, 2023 | |
| SPRB Spruce Biosciences | Reiterates: Outperform | $4 | $0.71 | +464.97% | 3 | May 16, 2023 | |
| KURA Kura Oncology | Reiterates: Outperform | $26 | $19.62 | +32.52% | 5 | May 11, 2023 | |
| ABCL AbCellera Biologics | Maintains: Outperform | $34 → $28 | $3.78 | +640.74% | 7 | May 5, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $70 → $81 | $44.19 | +83.30% | 9 | May 5, 2023 | |
| BCAB BioAtla | Reiterates: Neutral | $8 | $2.26 | +254.77% | 4 | Mar 24, 2023 | |
| PYXS Pyxis Oncology | Reiterates: Outperform | $14 | $4.45 | +214.61% | 2 | Mar 23, 2023 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $38 → $34 | $17.02 | +99.76% | 2 | Mar 10, 2023 | |
| GLTO Galecto | Reiterates: Outperform | $6 | $0.68 | +788.23% | 2 | Mar 10, 2023 | |
| EXEL Exelixis | Initiates: Outperform | $29 | $23.46 | +23.61% | 1 | Jan 26, 2023 | |
| OABI OmniAb | Initiates: Outperform | $13 | $4.44 | +192.79% | 1 | Dec 16, 2022 | |
| EDIT Editas Medicine | Downgrades: Neutral | $25 → $13 | $5.21 | +149.52% | 2 | Nov 18, 2022 | |
| IFRX InflaRx | Maintains: Underperform | $2.5 → $2 | $1.37 | +45.99% | 3 | May 13, 2022 | |
| ARGX argenx SE | Maintains: Neutral | n/a | $375.50 | - | 2 | Dec 20, 2021 | |
| AMGN Amgen | Maintains: Outperform | n/a | $273.94 | - | 1 | Apr 28, 2021 |
Aerovate Therapeutics
Apr 1, 2024
Maintains: Overweight
Price Target: $35
Current: $20.01
Upside: +74.91%
Insmed
Apr 1, 2024
Maintains: Overweight
Price Target: $55
Current: $24.72
Upside: +122.49%
United Therapeutics
Mar 7, 2024
Maintains: Overweight
Price Target: $309 → $325
Current: $234.33
Upside: +38.69%
Alnylam Pharmaceuticals
Feb 16, 2024
Maintains: Equal-Weight
Price Target: $171 → $161
Current: $143.95
Upside: +11.84%
Keros Therapeutics
Dec 8, 2023
Initiates: Overweight
Price Target: $60
Current: $56.39
Upside: +6.40%
Ultragenyx Pharmaceutical
Dec 8, 2023
Initiates: Overweight
Price Target: $72
Current: $42.54
Upside: +69.25%
Ventyx Biosciences
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $3.74
Upside: +1,557.75%
Ascendis Pharma
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $138.44
Upside: -35.71%
Viridian Therapeutics
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $13.26
Upside: +284.62%
BioMarin Pharmaceutical
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $80.76
Upside: +48.59%
23andMe Holding Co.
May 26, 2023
Reiterates: Outperform
Price Target: $6
Current: $0.50
Upside: +1,094.74%
Immunovant
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $27.44
Upside: -85.42%
Absci
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $4.74
Upside: +195.36%
Spruce Biosciences
May 16, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.71
Upside: +464.97%
Kura Oncology
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $19.62
Upside: +32.52%
AbCellera Biologics
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.78
Upside: +640.74%
Apellis Pharmaceuticals
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $44.19
Upside: +83.30%
BioAtla
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $2.26
Upside: +254.77%
Pyxis Oncology
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $4.45
Upside: +214.61%
ALX Oncology Holdings
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $17.02
Upside: +99.76%
Galecto
Mar 10, 2023
Reiterates: Outperform
Price Target: $6
Current: $0.68
Upside: +788.23%
Exelixis
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $23.46
Upside: +23.61%
OmniAb
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $4.44
Upside: +192.79%
Editas Medicine
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $5.21
Upside: +149.52%
InflaRx
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.37
Upside: +45.99%
argenx SE
Dec 20, 2021
Maintains: Neutral
Price Target: n/a
Current: $375.50
Upside: -
Amgen
Apr 28, 2021
Maintains: Outperform
Price Target: n/a
Current: $273.94
Upside: -